Investor Presentation First Nine Months of 2023
50
Investor presentation
First nine months of 2023
Phase 3 trial programme with CagriSema in type 2 diabetes,
REIMAGINE, was initiated in Q3 2023
CagriSema characteristics
REIMAGINE 1
vs placebo
CagriSema is a fixed dose
combination of injectable
cagrilintide 2.4 mg and semaglutide
2.4 mg
REIMAGINE 2
FDC trial
REIMAGINE 3
Add-on to insulin
Phase 3a programme with
CagriSema in T2D:
•
Aims to confirm efficacy and safety
across four global trials
REIMAGINE 4
H2H vs tirzepatide
REDEFINE 3
•
Global phase 3 trial programme
•
180 patients with T2D
40-week vs. placebo
• Primary endpoint: HbA1c
2700 patients with T2D, MET +/- SGLT-2i
68-week vs. semaglutide, cagrilintide and placebo
• Primary endpoint: HbA1c and bodyweight
•
•
270 patients with T2D, Basal insulin +/- MET
40-week vs. placebo
• Primary endpoint: HbA1c
1000 patients with T2D, MET +/- SGLT-2i
68-week vs. tirzepatide
• Primary endpoint: HbA1c and bodyweight
•
Expected completion during
2025/2026
7000 patients¹
CVOT - shared with
obesity programme
•
Event driven
O
Primary endpoint: 3-point MACE
2023
2024
2025
165% of patients with T2D, 35% without T2D
FDC: Fixed dose combination; T2D: Type 2 Diabetes; H2H: Head-to-head; CVOT: Cardiovascular outcomes trial; 3P: Three point; MACE: Major adverse cardiovascular event; MET: Metformin; SGLT-2i: sodium-glucose co-transporter-2 inhibitor
Note: CagriSema is a fixed dose combination of injectable cagrilintide 2.4 mg and injectable semaglutide 2.4 mg
2026
Novo NordiskⓇView entire presentation